Hikma Pharmaceuticals PLC HKMPF
Set alert
At close · Oct 30
- YTD
- +9.84%
- 1 year
- -5.43%
- Open
- 23.00
- Prev close
- 22.14
- Mkt cap
- 4.76B
- Vol
- 7
- Avg vol
- 442
- EPS
- 1.76
- P/E
- 13.07
More statistics
- Low
- 23.00
- High
- 23.00
- Earnings
- Feb 25, 2027
News
1 week ago marketbeat.com
Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress
Hikma Pharmaceuticals LON: HIK outlined a more centralized research and development strategy at the first event in its R&D Spotlight series, highlighting investments in respiratory, nasal, semi-solid…
1 month ago fool.com
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
1 month ago proactiveinvestors.co.uk
Panmure Liberum raises Hikma target price to 1,900p
Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its…
2 months ago proactiveinvestors.co.uk
Jefferies lifts Hikma target as CMO deal underpins growth story
Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade.…
2 months ago proactiveinvestors.co.uk
Citi sees Hikma discount as unwarranted after upgrade to forecasts
Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year results, arguing that the FTSE 100 drugmaker's valuation discount is no…
2 months ago proactiveinvestors.co.uk
Hikma boost as broker raises price target
Deutsche Bank has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,050p from 1,950p, reiterating its 'buy' rating on the FTSE 100 drugmaker. Kane Slutzkin said Hikma…
2 months ago proactiveinvestors.com
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel...
2 months ago proactiveinvestors.co.uk
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The…
3 months ago proactiveinvestors.co.uk
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive…
3 months ago proactiveinvestors.co.uk
Hikma recovery story still has further to run after recent rally, says Panmure
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has already rebounded 30% from its lows but Panmure Liberum believes the generic drugmaker still offers upside if it can rebuild investor confidence…
3 months ago proactiveinvestors.co.uk
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 price target, arguing the generic drugmaker's current valuation offers a compelling entry…
3 months ago proactiveinvestors.com
London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four
London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) chairman David Lenigas joined Proactive's Stephen Gunnion to discuss the Black Star gold project and the...
3 months ago proactiveinvestors.com
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...
3 months ago proactiveinvestors.com
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of...
6 months ago seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
6 months ago reuters.com
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the Middle East, a…
8 months ago seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
8 months ago seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
8 months ago proactiveinvestors.co.uk
Hikma Pharma tumbles on softer guidance as buyback fails to soften pill
Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026.…
8 months ago defenseworld.net
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF)
Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two…